Arrhythmogenic effects induced by coronary conversion of pulmonary big endothelin to endothelin: aggravation of this phenomenon in heritable hyperlipidemia.

[1]  L. Opie,et al.  Role of endothelin-A receptors in ischemic contracture and reperfusion injury. , 1998, Circulation.

[2]  T. Dschietzig,et al.  Pulmonary big endothelin affects coronary tone and leads to enhanced, ET(A)-mediated coronary constriction in early endothelial dysfunction. , 1997, Circulation.

[3]  J. Wu-Wong,et al.  Endothelin receptor antagonists: effect of serum albumin on potency and comparison of pharmacological characteristics. , 1997, The Journal of pharmacology and experimental therapeutics.

[4]  W. Kukovetz,et al.  Postischemic antiarrhythmic effects of angiotensin-converting enzyme inhibitors. Role of suppression of endogenous endothelin secretion. , 1996, Circulation.

[5]  M. Curtis,et al.  Effects of NO modulation on cardiac arrhythmias in the rat isolated heart. , 1995, Circulation research.

[6]  L. Opie,et al.  Binding of endothelin to plasma proteins and tissue receptors: effects on endothelin determination, vasoactivity, and tissue kinetics , 1995, FEBS letters.

[7]  P. Hunziker,et al.  Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure , 1995, The Lancet.

[8]  A. Garjani,et al.  Effects of Endothelin‐1 and the ETA-Receptor Antagonist, BQ123, on Ischemic Arrhythmias in Anesthetized Rats , 1995, Journal of cardiovascular pharmacology.

[9]  G. Ahlborg,et al.  Metabolism of Big endothelin-1 (1–38) and (22–38) in the human circulation in relation to production of endothelin-1 (1–21) , 1995, Regulatory Peptides.

[10]  Y. Sugishita,et al.  Increased Endothelin‐1 Binding Sites in the Cardiac Membranes in Rats with Chronic Heart Failure , 1995, Journal of cardiovascular pharmacology.

[11]  H. Riechers,et al.  Receptor Selectivity of Endothelin Antagonists and Prevention of Vasoconstriction and Endothelin‐Induced Sudden Death , 1995, Journal of cardiovascular pharmacology.

[12]  S. Ozaki,et al.  Synergistic inhibition by BQ‐123 and BQ‐788 of endothelin‐1‐induced contractions of the rabbit pulmonary artery , 1994, British journal of pharmacology.

[13]  H. Kasai,et al.  Pharmacological properties of endothelin receptor subtypes mediating positive inotropic effects in rabbit heart. , 1994, The American journal of physiology.

[14]  M. Kinoshita,et al.  Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure. , 1994, Journal of the American College of Cardiology.

[15]  W. Edwards,et al.  Endothelin in human congestive heart failure. , 1994, Circulation.

[16]  J. Hodgson,et al.  Evidence that selective endothelial dysfunction may occur in the absence of angiographic or ultrasound atherosclerosis in patients with risk factors for atherosclerosis. , 1994, Journal of the American College of Cardiology.

[17]  K. Fujita,et al.  Conversion of big ET-1 in the rat lung: role of phosphoramidon-sensitive endothelin-1-converting enzyme. , 1994, The American journal of physiology.

[18]  V. Breu,et al.  Potent vasoconstriction mediated by endothelin ETB receptors in canine coronary arteries. , 1994, Circulation research.

[19]  D. Stewart,et al.  Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. , 1993, The New England journal of medicine.

[20]  Y. Urade,et al.  ETB receptor antagonist, IRL 1038, selectively inhibits the endothelin-induced endothelium-dependent vascular relaxation. , 1993, European journal of pharmacology.

[21]  T. Watanabe,et al.  Role of endogenous endothelin in extension of rabbit myocardial infarction. , 1993, Journal of cardiovascular pharmacology.

[22]  A. Doherty,et al.  In vitro and in vivo studies with a series of hexapeptide endothelin antagonists. , 1993, Journal of cardiovascular pharmacology.

[23]  J. Parratt,et al.  Preconditioning of the ischaemic myocardium; involvement of the l‐arginine nitric oxide pathway , 1992, British journal of pharmacology.

[24]  P. Binkley,et al.  Plasma Endothelin Correlates With the Extent of Pulmonary Hypertension in Patients With Chronic Congestive Heart Failure , 1992, Circulation.

[25]  S. Henke,et al.  DesArg9D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin (desArg10-[Hoe140]) is a bradykinin B1 receptor antagonist , 1991 .

[26]  C. Patrono,et al.  Proarrhythmic Activity of Intracoronary Endothelin in Dogs: Relation to the Site of Administration and to Changes in Regional Flow , 1991, Journal of cardiovascular pharmacology.

[27]  H. Drexler,et al.  Modulation of coronary vasomotor tone in humans. Progressive endothelial dysfunction with different early stages of coronary atherosclerosis. , 1991, Circulation.

[28]  H. Koike,et al.  Electrophysiological effects of endothelin-1 on canine myocardial cells. , 1991, Journal of cardiovascular pharmacology.

[29]  B. Schölkens,et al.  DesArg9-D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin (desArg10-[Hoe140]) is a potent bradykinin B1 receptor antagonist. , 1991, European journal of pharmacology.

[30]  M. Naruse,et al.  Is big endothelin converted to endothelin-1 in circulating blood? , 1991, Journal of cardiovascular pharmacology.

[31]  H. Koike,et al.  Evidence for direct arrhythmogenic action of endothelin. , 1990, Biochemical and biophysical research communications.

[32]  E. Ohlstein,et al.  The effect of diltiazem on the coronary haemodynamic and cardiac functional effects produced by intracoronary administration of endothelin‐1 in the anaesthetized dog , 1990, British journal of pharmacology.

[33]  M. Clozel,et al.  Effects of Endothelin on the Coronary Vascular Bed in Open-Chest Dogs , 1989, Circulation research.

[34]  A. Maseri,et al.  Intracoronary endothelin induces myocardial ischemia by small vessel constriction in the dog. , 1989, The American journal of cardiology.

[35]  M. Yanagisawa,et al.  INCREASED PLASMA CONCENTRATIONS OF ENDOTHELIN-1 AND BIG ENDOTHELIN-1 IN ACUTE MYOCARDIAL INFARCTION , 1989, The Lancet.

[36]  G. Feuerstein,et al.  Lethal ischemia due to intracoronary endothelin in pigs. , 1989, The American journal of physiology.

[37]  J. Parratt.  Eicosanoids and Arrhythmogenesis , 1989 .

[38]  R. Campbell,et al.  The Lambeth Conventions: guidelines for the study of arrhythmias in ischaemia infarction, and reperfusion. , 1988, Cardiovascular research.

[39]  Sadao Kimura,et al.  A novel potent vasoconstrictor peptide produced by vascular endothelial cells , 1988, Nature.

[40]  H. Mest,et al.  Relevance of eicosanoids for biochemical regulation of cardiac rhythm disturbances. , 1987, Biomedica biochimica acta.

[41]  P. Ganz,et al.  Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. , 1986, The New England journal of medicine.

[42]  Y. Watanabe,et al.  The effect of selective breeding on the development of coronary atherosclerosis in WHHL rabbits. An animal model for familial hypercholesterolemia. , 1985, Atherosclerosis.

[43]  J. Bortz,et al.  Verteilungsfreie Methoden in der Biostatistik , 1982 .

[44]  A. Dembińska-kieć,et al.  Atherosclerosis decreased prostacyclin formation in rabbit lungs and kidneys. , 1979, Prostaglandins.

[45]  S. Holm.  A Simple Sequentially Rejective Multiple Test Procedure , 1979 .

[46]  Smith Pm.  Letter: Upper gastrointestinal endoscopy. , 1974, The Lancet.

[47]  Y. Watanabe,et al.  A heritable hyperlipemic rabbit. , 1975, Jikken dobutsu. Experimental animals.